How to Build an Evidence Map for a Research Compound

What an Evidence Map Is

An evidence map is a structured view of a research field. Unlike a narrative that selects a few notable findings, the map organizes evidence by model, question, design, and confidence. For a peptide or related compound, this may include molecular identity, target pharmacology, in-vitro work, animal models, human studies, safety reports, regulatory history, and unresolved gaps.

Begin With Identity

The map must define the compound precisely. Record the sequence or structure, modifications, salt or counterion, known aliases, and distinctions from similarly named materials. If the marketplace name is ambiguous, the evidence map should say that literature cannot be assigned confidently until identity is verified.

Define the Research Questions

A single compound may be studied for receptor pharmacology, metabolism, tissue response, cognition, inflammation, or another domain. These questions should not be combined into one overall evidence score. A compound can have strong evidence for target engagement and weak evidence for organism-level outcomes. Mapping by question preserves that distinction.

Sort by Evidence Model

Separate biochemical and binding assays, cell studies, ex-vivo work, animal studies, human observational research, controlled human trials, and approved-product evidence. Within each category, record the model, sample size, comparator, exposure, endpoint, main findings, and limitations.

Assess Quality, Not Just Quantity

Ten similar low-quality studies do not necessarily outweigh one rigorous contradictory study. Evaluate randomization, blinding, prespecification, material characterization, statistical appropriateness, attrition, selective reporting, and independent replication. Note whether many papers come from the same laboratory or research group.

Create a Safety Layer

Safety evidence deserves its own map. Include toxicology, adverse events, immunogenicity, off-target effects, dose and exposure relationships, contraindication signals, and duration of follow-up. Absence of reported harm in a small study should not be converted into evidence of safety.

Add Regulatory and Development Status

Record whether the molecule is endogenous, investigational, discontinued, used in an approved drug, or lacking an approved product. Include trial phases, sponsor information, regulatory notices, and the date of review. Status changes over time, so an evidence map should be maintained rather than published once and forgotten.

Display Gaps Explicitly

A useful map makes missing evidence visible. Examples include no independent replication, no human pharmacokinetics, no long-term toxicology, uncertain product identity, or no studies of the marketed blend. Unknown should be treated as a finding about the evidence base, not as permission to assume a favorable answer.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.